Evidence map›Paper›PMID 39672944›Full record

ArticleAnnals of hematology2024

Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant.

Giorgia Ranucci, Camilla Page, Enrica Marchionni, Chiara Minotti, Giorgia Silvestrini, Susanna Gastaldi, Giada Pacitto, Laura Cicconi, Annalisa Biagi, Valentina Ferradini and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Giorgia Ranucci *Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Camilla Page *Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Enrica MarchionniMedical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy.
Chiara MinottiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Giorgia SilvestriniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Susanna GastaldiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Giada PacittoDepartment of Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, Latina, Italy.
Laura CicconiDepartment of Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, Latina, Italy.
Annalisa BiagiDepartment of Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, Latina, Italy.
Valentina FerradiniMedical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy.
Enrico AttardiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. enrico.attardi@gmail.com.ORCID http://orcid.org/0009-0008-4801-5048
Giuseppe NovelliDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Federica SangiuoloDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Maria Teresa Voso *Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Carmelo Gurnari *Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. carmelogurnari31@gmail.com.ORCID http://orcid.org/0000-0001-6829-5544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, germline variants have also been found as contributors of disease etiology in myeloproliferative neoplasms (MPN). The consideration of such inherited traits is crucial for clinical management of patients, particularly with regards to indication for allogeneic hematopoietic cell transplant (allo-HCT) and donor selections. Herein, we describe the very instructive case of a 49-year-old woman diagnosed with JAK2 V617F-positive primary myelofibrosis (PMF) who was found to also carry a germline variant in the SH2B3 gene, detailing clinical management, donor selection process for allo-HCT purposes, and appropriate genetic counseling.

Indexed as

Adaptor Proteins, Signal TransducingGerm-Line MutationHematopoietic Stem Cell TransplantationJanus Kinase 2Primary MyelofibrosisAllograftsDonor SelectionFemaleHumansIntracellular Signaling Peptides and ProteinsMiddle AgedTransplantation, HomologousAdaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsJAK2 protein, humanJanus Kinase 2SH2B3 protein, humanGenetic counselingGermline predispositionMyeloid malignancies

Identifiers

PMID39672944

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.